Metagenomi develops genetic medicines using a proprietary genome editing platform derived from metagenomics research. The company's toolkit encompasses multiple modalities including nuclease-based genome editing, base editors, RNA-mediated integration through prime editing, and DNA-mediated integration via CRISPR-associated transposases. These technologies are applied toward therapeutic development across multiple disease areas.
The company has established partnerships to advance its platform technologies. A collaboration and license agreement with Ionis Pharmaceuticals covers research, development, and commercialization of investigational medicines using Metagenomi's genome editing technologies. Additionally, Metagenomi holds a development, option, and license agreement with Affini-T Therapeutics to develop and commercialize gene-edited TCR-based therapeutic products specifically for cancer treatment, prevention, or diagnosis.
Metagenomi operates as a clinical-stage biotechnology company with 124 full-time employees and is headquartered in Emeryville, California. The company was incorporated in 2016 and is publicly listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.36 | $-2.36 | — |